New drug combo aims to extend life in aggressive lung cancer

NCT ID NCT04699838

Ongoing Disease control Sponsor: Muhammad Furqan Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding two drugs (durvalumab and ceralasertib) after standard chemo-immunotherapy can help control extensive-stage small cell lung cancer. About 30 people who have not had prior treatment will receive the combination. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab and ceralasertib (oral drugs given after initial chemotherapy and immunotherapy)
What this could lead to: If it works, this could offer a new maintenance treatment option to help control extensive-stage small cell lung cancer for longer.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The added drugs may cause side effects and may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Locations

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Indianapolis, Indiana, 46202, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
University of Illinois Medical Center

Chicago, Illinois, 60612, United States
University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States
University of Maryland

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.